Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.08 USD | -1.06% | +4.08% | -8.25% |
Apr. 22 | European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations | MT |
Apr. 16 | QIAGEN NV : Deutsche Bank reiterates its Buy rating | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's enterprise value to sales, at 4.72 times its current sales, is high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.25% | 9.09B | A | ||
+1.12% | 42.59B | B | ||
+6.77% | 40.65B | B- | ||
+45.26% | 40.57B | A | ||
-11.96% | 26.77B | C | ||
+6.01% | 24.81B | B- | ||
-24.92% | 18.17B | B | ||
-3.63% | 11.7B | C+ | ||
+27.16% | 12.05B | C+ | ||
+7.30% | 11.1B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QGEN Stock
- Ratings Qiagen N.V.